Breaking AI & Tech News Analyzed

Breakthrough: Baking Sourdough with 5,000‑Year‑Old YeastScientists have successfully baked a sourdough loaf using yeast strains isolated from the 5,000‑year‑old Alpine mummy known as Ötzi the Iceman. The experiment demonstrates that ancient microorganisms can still perform modern fermentation processes.How the Ancient Yeast Was Extracted and TestedResearchers from Eurac Research's Institute for Mummy Studies carefully sampled the microbial layer on Ötzi’s skin and clothing, then cultured the yeast under cold‑room conditions before introducing it into a standard sourdough starter.Source: Ötzi’s preserved remains, discovered 1991 near the Italy‑Austria border.Age of yeast: ~5,000 years.Lead microbiologist: Mohamed Sarhan.Fermentation time: dough rose in 24 hours, comparable to modern baker’s yeast.Scientific Metrics: Fermentation Times and ViabilityThe ancient yeast produced a normal rise within 24 hours, indicating viable metabolic activity despite millennia of dormancy. No quantitative yield data were released, but the rapid leavening suggests comparable enzymatic efficiency to contemporary strains.Implications for Food Science and ArchaeologyThis result bridges paleomicrobiology and culinary science, offering a tangible link to prehistoric food practices. It also opens avenues for studying ancient microbial genetics, which could reveal lost fermentation traits.Next Steps: Brewing Beer and Expanding Ancient Microbe ResearchThe team plans to collaborate with German brewer Weihenstephan to test the yeast’s suitability for beer production. Further investigations will assess the genetic profile of the strain and explore other potential applications in food and biotechnology.

The Lead: Biotech Barbie's Mission to Edit Human DNA Cathy Tie, a Canadian entrepreneur known as "Biotech Barbie," is pursuing a controversial mission to genetically modify embryos to prevent hereditary diseases, following in the footsteps of her ex-husband He Jiankui, who served prison time for creating the world's first gene-edited babies. Despite global bans on germline gene editing for reproductive purposes, Tie aims to conduct this work openly with regulatory approval and venture capital funding. The Technical Breakthrough: Gene Editing Made Accessible Since the invention of the Crispr-Cas9 gene editing tool in 2012, the technical process of altering DNA has become relatively straightforward. "The hardest thing about genetically engineering a baby is getting permission to do it; the technical part is not particularly complicated," the article explains. The process is compared to using "find, copy, cut and paste functions on a computer" and doesn't require extensive expertise in molecular biology. Germline gene editing—altering eggs, sperm, or early embryos—is particularly significant because changes are passed down to future generations, potentially altering human evolution permanently. This is why such procedures are banned in the UK, US, and China, with international agreement against research that could result in gene-edited babies. The Financial Landscape: Billionaires Investing in Genetic Engineering Money is flowing into human genetic engineering, with some of the world's richest men investing in companies pursuing similar goals. Preventive, a gene editing startup launched in October 2025 with the aim of "preventing disease before birth," has attracted investment from OpenAI's Sam Altman, his husband Oliver Mulherin, and Coinbase CEO Brian Armstrong. Armstrong has coined the term "the Gattaca stack"—referencing the dystopian film about a genetically engineered society—which includes technologies for "disease prevention, or enhancement" of babies. This suggests a growing interest not just in preventing diseases but in enhancing human traits. Preimplantation genetic testing (PGT), already common in the US fertility treatments, allows parents to "choose the embryo that best matches what you want," with companies like Nucleus Genomics advertising on subways with the tagline "Have your best baby." The Global Impact: A New Biological Arms Race? "There's a big geopolitical component to this," Tie states, referring to the growing interest in genetic engineering. China, where Tie was banned from entering, has already demonstrated what gene editing can do—Chinese researchers made the first edits to human embryos in 2015, and Tie's ex-husband He Jiankui created the first gene-edited babies, twin girls known as Lulu and Nana. Since his release from prison in 2022, He has become an unlikely social media star with close to 150,000 followers on X, making unrepentant posts about "designer babies" being "inevitable." Meanwhile, China's biotechnology ambitions have expanded, with Premier Li Qiang announcing new regulations emphasizing "the need to promote innovative development" and "accelerate R&D; and commercialization." In response to China's announcement, Tie posted: "Welcome to the dawn of the biological arms race." The Future Outlook: Inevitable Genetic Modification "Biology is a double-edged sword – it can be used for good, to heal people, or it can be used for bad," Tie explains. "Stopping this research will only drive bad actors to do it secretively. There is no way to stop this. This is inevitable. The only way to proceed is to do it openly and transparently." Tie named her first human gene-editing company the Manhattan Project, drawing a parallel between the nucleus of the atom and the nucleus of the cell. "In the 20th century, we understood the nucleus of the atom very well, and we learned some very difficult lessons via weapons and wars," she says. "I don't want to see the same happen with the second nucleus." Despite her declared commitment to openness, much of Tie's work remains shrouded in secrecy. Her first company, the Manhattan Project, has since shut down due to what she calls a "fundamental mistake" in choosing a co-founder. She has since launched Origin Genomics, continuing her pursuit of genetic modification of embryos.

Researchers from Stanford, Oxford and UC San Diego have demonstrated a proof‑of‑concept wearable ultrasound patch that can monitor a baby’s heart rate and blood flow continuously, aiming to reduce false alarms and missed complications in pregnancy.A Patch That Turns Ultrasound Into a Wearable SensorThe device, dubbed UPatch, adheres to the abdomen and remains operational for hours, capturing real‑time images of the foetus and umbilical cord. Unlike intermittent hospital scans, the patch records a continuous stream of data, allowing clinicians to establish a personal baseline for each pregnancy and spot deviations instantly.Trial Results Show Near‑Parity With Conventional ScansIn a study published in Nature Biotechnology, the team evaluated the patch in two cohorts:62 pregnant participants – single‑time‑point blood‑flow measurements from UPatch matched those from standard handheld ultrasound.52 women – continuous monitoring revealed dynamic fluctuations in fetal blood flow that brief scans would miss.A pre‑eclamptic case where UPatch detected severe intra‑uterine growth restriction, prompting a timely caesarean delivery and preventing stillbirth.Lead author Tom Park highlighted that the technology captures transient changes without over‑diagnosing, addressing a key limitation of current intermittent methods.Potential Shift in Prenatal Care and Global HealthSenior author Prof Sheng Xu emphasized that continuous monitoring could become a routine part of prenatal visits, especially in low‑resource settings where access to skilled sonographers is limited. Dr Antoniya Georgieva noted the broader impact: reducing stillbirth rates, providing richer data for research, and enabling earlier interventions for conditions like pre‑eclampsia.Roadmap Toward a Fully Wireless Home‑Use SystemThe current prototype is tethered to external electronics for placement, but the team is already engineering a wireless version that patients could wear during daily activities and at home. Their long‑term vision is a seamless, battery‑efficient system that integrates with tele‑health platforms, delivering real‑time alerts to clinicians wherever the mother is.